Aptabio Therapeutics, Inc.
Clinical trials sponsored by Aptabio Therapeutics, Inc., explained in plain language.
-
New drug combo takes on advanced cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called APX-343A, given alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shows any si…
Phase: PHASE1 • Sponsor: Aptabio Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 11:19 UTC
-
New pill for macular degeneration enters first human tests
Disease control Recruiting nowThis early-stage study tests an oral drug called ABF-101 in healthy adults and people with age-related macular degeneration (AMD). The main goal is to check safety and how the body processes the drug. If successful, it could lead to a new way to control AMD, a leading cause of vi…
Phase: PHASE1 • Sponsor: Aptabio Therapeutics, Inc. • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New drug aims to shield kidneys during heart scans
Disease control Recruiting nowThis study tests whether a new drug, APX-115, can prevent kidney injury caused by contrast dye used during heart procedures. About 280 adults with heart disease will receive either the drug or a placebo. The goal is to see if the drug is safe and reduces kidney damage.
Phase: PHASE2 • Sponsor: Aptabio Therapeutics, Inc. • Aim: Disease control
Last updated May 04, 2026 16:23 UTC